Any current/future new fundraising through debt or equity?

The transcript does not explicitly mention any current or planned fundraising through debt or equity. However, it mentions company expansion plans including management team growth and plant upgrades. Ashwani Khemka mentioned expansion of the management team in light of a "fundraiser," indicating some form of capital raising is planned or ongoing, but details such as amount, type (debt/equity), or timing are not provided. The company is investing in new facilities such as the Hindustan Antibiotic JV with a total capex of around INR 35 to 38 crores, with about 10% spent so far. No specific fundr

Any current/future capex/capital investment/strategic investment?

Total capex for Hindustan Antibiotic Limited (HAL) JV: INR 35-38 crores; 10% invested so far; 70% of major equipment ordered; plant layout finalizing; civil work to start soon; revenue expected from Q4 FY25. Prague facility capex: INR 3 to 3.5 crores already spent; includes packaging line delayed to late March due to Red Sea embargo; targeting entry into European and American markets. Current facility upgrades (Dehradun and Mumbai): INR 4-5 crores planned; includes regulatory approvals and capacity enhancements. Financing through preference shares and internal accruals; working with HR firm

Future growth expectations in sales/revenue/volumes?

The company is poised to report good results and revenues in the coming years, supported by strong tie-ups and good market access. Dehradun facility upgradation is underway, with upcoming inspections expected to enable approvals in multiple Latin American countries and potentially East European countries by end of 2024, expanding market reach. Focus on expanding export markets, especially in Latin America, Francophone Africa, and East Africa, targeting new countries for growth. Management team expansion with addition of 15-20 senior management personnel will support scaling operations.

Future growth expectations in earnings/operating earnings/profits/EPS?

The company is poised to report good results and revenues in the coming years due to strong tie-ups and good market access. Expansion plans include plant upgrades (notably Dehradun) and a new HAL facility expected to be operational from October 2024. New senior management hiring underway to support growth. Injection segment showing rapid growth with increased demand from new geographies. The planned revenue mix is targeted at maintaining 75% export and 25% domestic sales. Addition of 15-20 new senior management personnel is expected, supporting scaling operations. Ongoing expansions into Latin

Sanjiv.Parant.Q3 FY24Pharmaceuticals & Biotechnology

Sanjiv.Parant. Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹165P/E: 27.7Market Cap: ₹208 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The company is poised to report good results and revenues in the coming years, supported by strong tie-ups and good market access.
Dehradun facility upgradation is underway, with upcoming inspections expected to enable approvals in multiple Latin American countries and potentially East European countries by end of 2024, expanding market reach.
Focus on expanding export markets, especially in Latin America, Francophone Africa, and East Africa, targeting new countries for growth.
Management team expansion with addition of 15-20 senior management personnel will support scaling operations.
Continued product portfolio expansion with 15-20 new products annually, adding to injectables and orals, primarily targeting chronic diseases.
Capacity utilization is growing, with injectables at 70% and orals at 35%, and an expectation of sustained growth in injectables.
Government tenders and private markets are competitive, with some regions having stable or growing market share.
The company aims to maintain a 75% export and 25% domestic revenue mix.

Margin guidance

Category 3

The company is poised to report good results and revenues in the coming years due to strong tie-ups and good market access.
Expansion plans include plant upgrades (notably Dehradun) and a new HAL facility expected to be operational from October 2024.
New senior management hiring underway to support growth.
Injection segment showing rapid growth with increased demand from new geographies.
The planned revenue mix is targeted at maintaining 75% export and 25% domestic sales.
Addition of 15-20 new senior management personnel is expected, supporting scaling operations.
Ongoing expansions into Latin America, Francophone Africa, and East European countries.
Company expects margins to normalize post initial contraction from new products.
Long-term aspirational revenue targets for FY27 and FY28 were queried but specific numbers were not disclosed.

See what Sanjiv.Parant. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The transcript does not explicitly mention any current or planned fundraising through debt or equity.
However, it mentions company expansion plans including management team growth and plant upgrades.
Ashwani Khemka mentioned expansion of the management team in light of a "fundraiser," indicating some form of capital raising is planned or ongoing, but details such as amount, type (debt/equity), or timing are not provided.
The company is investing in new facilities such as the Hindustan Antibiotic JV with a total capex of around INR 35 to 38 crores, with about 10% spent so far.
No specific fundraising details like amounts or instruments were disclosed in this call transcript.

Order book

Yes

- The transcript does not explicitly mention specific current or expected orderbook or pending orders figures. - However, Ashwani Khemka mentions good tie-ups and good market access, implying a healthy order pipeline. - There is a focus on increased demand, especially from newer geographies in the injectables segment. - The company expects good revenues and results going forward, supported by ongoing plant upgrades and approvals. - The HAL project is progressing as planned with machinery ordered and site activities beginning, suggesting future order fulfillment capacity increase. - They mention efforts to expand export markets (Latin America, Francophone Africa, East European countries), which may contribute to future order growth. - Product additions and regulatory approvals aim to drive growth, further indirectly pointing to an expected growing orderbook. No specific quantitative figures for orders were disclosed in the provided transcript.

See what Sanjiv.Parant. management said on order book — free account, 30 seconds.

Capex plans

Yes

Total capex for Hindustan Antibiotic Limited (HAL) JV: INR 35-38 crores; 10% invested so far; 70% of major equipment ordered; plant layout finalizing; civil work to start soon; revenue expected from Q4 FY25.
Prague facility capex: INR 3 to 3.5 crores already spent; includes packaging line delayed to late March due to Red Sea embargo; targeting entry into European and American markets.
Current facility upgrades (Dehradun and Mumbai): INR 4-5 crores planned; includes regulatory approvals and capacity enhancements.
Financing through preference shares and internal accruals; working with HR firm to expand senior management in line with fundraising.
Strategic investments to access regulated and semi-regulated markets, expanding product portfolio and market presence.

Track Sanjiv.Parant. — get its next earnings analysis in your feed

How does Sanjiv.Parant. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSanjiv.Parant.

Rev 2Mar 3

See where Sanjiv.Parant. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Sanjiv.Parant. rank in Pharmaceuticals & Biotechnology?

Compare Sanjiv.Parant. against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Sanjiv.Parant.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →